Document Detail


Metastatic pancreatic adenocarcinoma: current standards, future directions.
MedLine Citation:
PMID:  19636248     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pancreatic cancer is the fourth most common cause of cancer death in the United States. In the landmark study in 1997, which established the central although modest role of gemcitabine in this disease, progress has been incremental. Significant developments have been an increased acceptance for combination chemotherapy in patients with good performance status in addition to an increased understanding of tumorigenesis. The parallel technologic and engineering developments that have occurred hold the promise of exploiting this understanding. This review attempts to summarize the standard therapeutic approach to metastatic pancreatic cancer and point to areas that hold promise for the future.
Authors:
Austin Duffy; Shivaani Kummar
Related Documents :
18533808 - Novel advances in pancreatic cancer treatment.
19481338 - E1b-55kd-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti...
3062098 - Pancreatic function tests in the diagnosis of pancreatic cancer.
18935928 - Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?
22443228 - Current status of targeted therapies in advanced gastric cancer.
15183948 - Application of tnm, 2002 version, in localized renal cell carcinoma: is it able to pred...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural; Review    
Journal Detail:
Title:  American journal of therapeutics     Volume:  17     ISSN:  1536-3686     ISO Abbreviation:  Am J Ther     Publication Date:    2010 Jan-Feb
Date Detail:
Created Date:  2010-01-22     Completed Date:  2010-03-03     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  79-85     Citation Subset:  IM    
Affiliation:
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy*,  pathology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Clinical Trials as Topic
Deoxycytidine / administration & dosage,  analogs & derivatives
Humans
Neoplasm Metastasis
Pancreatic Neoplasms / drug therapy*,  pathology
Chemical
Reg. No./Substance:
951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical impl...
Next Document:  Acute phosphate nephropathy.